Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …

Multiple mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) have been identified in EGFR-mutant non-small cell lung cancer …

The epidermal growth factor receptor (EGFR) is a well‐characterized oncogene that is
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …

In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of
immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of …

Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

Background The mechanism of primary resistance to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small-cell lung cancer …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …

Treatment with receptor-tyrosine kinase inhibitors (TKIs) has improved progression-free and
overall survival in patients with advanced non-small cell lung cancer (NSCLC). One major …

With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …